Characteristic | Patients < 65 years | Patients > 65 years | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |  | Univariate analysis | Multivariable analysis |  | Univariate analysis | Multivariable analysis | ||||||||
 | N | RER | 95% CI | P | RER | 95% CI | P | N | RER | 95% CI | P | RER | 95% CI | P |
Age | Â | Â | Â | .06 | Â | Â | .10 | Â | Â | Â | Â | Â | Â | Â |
< 40 | 33 | 1 | Â | Â | 1 | Â | Â | 0 | Â | Â | Â | Â | Â | Â |
40-50 | 98 | 1.03 | 0.51-2.08 | Â | 0.69 | 0.21-2.24 | Â | 0 | Â | Â | Â | Â | Â | Â |
50-60 | 101 | 1.52 | 0.76-3.03 | Â | 1.38 | 0.46-5.18 | Â | 0 | Â | Â | Â | Â | Â | Â |
> 60 | 44 | 2.16 | 0.99-4.66 | Â | 1.93 | 0.56-6.57 | Â | 154 | Â | Â | Â | Â | Â | Â |
Grade | Â | Â | Â | .03 | Â | Â | .95 | Â | Â | Â | .34 | Â | Â | Â |
I | 31 | 1 | Â | Â | 1 | Â | Â | 24 | 1 | Â | Â | Â | Â | Â |
II | 131 | 2.23 | 0.80-6.28 | Â | 1.24 | 0.31-5.03 | Â | 74 | 3.10 | 0.43-22.4 | Â | Â | Â | Â |
III | 75 | 3.48 | 1.22-9.94 | Â | 1.27 | 0.30-5.45 | Â | 44 | 4.23 | 0.56-31.8 | Â | Â | Â | Â |
Histological type | Â | Â | Â | .80 | Â | Â | Â | Â | Â | Â | .37 | Â | Â | Â |
Ductal | 223 | 1 | Â | Â | Â | Â | Â | 124 | 1 | Â | Â | Â | Â | Â |
Other | 15 | 1.12 | 0.46-2.71 | Â | Â | Â | Â | 18 | 1.49 | 0.62-3.61 | Â | Â | Â | Â |
Tumor stage | Â | Â | Â | < .001 | Â | Â | .33 | Â | Â | Â | .01 | Â | Â | .09 |
pT1 | 137 | 1 | Â | Â | 1 | Â | Â | 59 | 1 | Â | Â | 1.00 | Â | Â |
pT2 | 109 | 2.67 | 1.41-3.64 | Â | 1.42 | 0.73-2.76 | Â | 71 | 5.47 | 0.83-35.9 | Â | 4.26 | 0.71-25.4 | Â |
pT3/4 | 22 | 4.26 | 2.29-7.94 | Â | 1.79 | 0.81-3.95 | Â | 18 | 13.2 | 1.90-92.1 | Â | 7.90 | 1.18-52.9 | Â |
Nodal stage | Â | Â | Â | < .001 | Â | Â | < .001 | Â | Â | Â | .02 | Â | Â | .43 |
Negative | 204 | 1 | Â | Â | 1 | Â | Â | 109 | 1 | Â | Â | 1.00 | Â | Â |
Positive | 69 | 5.03 | 3.32-7.62 | Â | 5.82 | 3.16-10.7 | Â | 36 | 2.76 | 1.20-6.35 | Â | 1.48 | 0.56-3.92 | Â |
ER status | Â | Â | Â | .11 | Â | Â | Â | Â | Â | Â | .91 | Â | Â | Â |
Negative | 87 | 1 | Â | Â | Â | Â | Â | 40 | 1 | Â | Â | Â | Â | Â |
Positive | 126 | 0.70 | 0.45-1.09 | Â | Â | Â | Â | 95 | 0.95 | 0.42-2.17 | Â | Â | Â | Â |
PgR status | Â | Â | Â | .25 | Â | Â | Â | Â | Â | Â | .58 | Â | Â | Â |
Negative | 84 | 1 | Â | Â | Â | Â | Â | 55 | 1 | Â | Â | Â | Â | Â |
Positive | 123 | 0.77 | 0.49-1.21 | Â | Â | Â | Â | 81 | 0.80 | 0.36-1.77 | Â | Â | Â | Â |
HER2 status | Â | Â | Â | .19 | Â | Â | Â | Â | Â | Â | .89 | Â | Â | Â |
Negative | 143 | 1 | Â | Â | Â | Â | Â | 105 | 1 | Â | Â | Â | Â | Â |
Positive | 19 | 1.57 | 0.80-3.09 | Â | Â | Â | Â | 4 | 0.85 | 0.09-8.40 | Â | Â | Â | Â |
ALDH1 status | Â | Â | Â | .008 | Â | Â | .02 | Â | Â | Â | .35 | Â | Â | Â |
Negative | 77 | 1 | Â | Â | 1 | Â | Â | 63 | 1 | Â | Â | Â | Â | Â |
Positive | 116 | 2.12 | 1.22-3.68 | Â | 2.36 | 1.17-4.73 | Â | 61 | 0.68 | 0.30-1.53 | Â | Â | Â | Â |